Avalo Therapeutics (AVTX) Operating Income (2014 - 2026)
Avalo Therapeutics' (AVTX) quarterly Operating Income came in at -$20.9 million in Q1 2026, down 42.48% YoY from -$36.3 million in Q1 2025, and down 5.87% on a QoQ basis from -$19.7 million in Q4 2025.
Avalo Therapeutics (AVTX) Operating Income (2014 - 2026) Analysis & Trends
Avalo Therapeutics (AVTX) has 13 years of Operating Income data on file, last reported at -$20.9 million in Q1 2026.
- Quarterly Operating Income fell 42.48% year-over-year to -$20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$79.2 million (down 57.01% YoY) and the FY2025 annual result came in at -$72.9 million, down 6.44% from the prior year.
- Operating Income eased to -$20.9 million in Q1 2026, from -$19.7 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of $4.1 million in Q3 2022 to a low of -$32.8 million in Q1 2024.
- A 5-year average of -$13.4 million and a median of -$12.9 million in 2024 frame the typical range for Operating Income.
- Annual changes were most pronounced in 2022 — Operating Income soared 124.87% — and 2024, when it slumped 272.69%.
- Tracing AVTX's Operating Income over 5 years: stood at -$8.9 million in 2022, then advanced by 13.52% to -$7.7 million in 2023, then tumbled by 73.82% to -$13.3 million in 2024, then tumbled by 48.31% to -$19.7 million in 2025, then decreased by 5.87% to -$20.9 million in 2026.
- The last three Operating Income figures came in at -$20.9 million (Q1 2026), -$19.7 million (Q4 2025), and -$19.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Avalo Therapeutics | 854.16 Mn | 453.89 Mn | - | -31.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -31.52 Mn |
| Mar 31, 2026 | -20.90 Mn |
| Dec 31, 2025 | -19.74 Mn |
| Sep 30, 2025 | -19.20 Mn |
| Jun 30, 2025 | -19.32 Mn |
| Mar 31, 2025 | -14.67 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | -12.86 Mn |
| Jun 30, 2024 | -9.58 Mn |
| Mar 31, 2024 | -32.77 Mn |
| Dec 31, 2023 | -7.66 Mn |
| Sep 30, 2023 | -3.75 Mn |
| Jun 30, 2023 | -7.15 Mn |
| Mar 31, 2023 | -8.79 Mn |
| Dec 31, 2022 | -8.86 Mn |
| Sep 30, 2022 | 4.10 Mn |
| Jun 30, 2022 | -11.83 Mn |
| Mar 31, 2022 | -20.85 Mn |
| Dec 31, 2021 | -17.96 Mn |
| Sep 30, 2021 | -16.46 Mn |